Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. [electronic resource]
Producer: 20071113Description: 3465-70 p. digitalISSN:- 0250-7005
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- adverse effects
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Female
- Humans
- Hypertension -- chemically induced
- Incidence
- Male
- Middle Aged
- Neovascularization, Pathologic -- drug therapy
- Protein Kinase Inhibitors -- pharmacology
- United States -- epidemiology
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
- Vascular Endothelial Growth Factor Receptor-1 -- metabolism
- Vascular Endothelial Growth Factor Receptor-2 -- metabolism
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.